Fosun International’s Cymabay Therapeutics CBAY Stock Holding History

Fosun International’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-78,529	Closed	-$492K	–	77
2022 Q4	$492K	Sell	78,529 -185,000	-70%	-$703K	0.04%	52
2022 Q3	$923K	Hold	263,529	–	–	0.1%	52
2022 Q2	$778K	Hold	263,529	–	–	0.11%	56
2022 Q1	$819K	Hold	263,529	–	–	0.07%	112
2021 Q4	$890K	Hold	263,529	–	–	0.05%	135
2021 Q3	$962K	Hold	263,529	–	–	0.05%	124
2021 Q2	$1.15M	Hold	263,529	–	–	0.07%	105
2021 Q1	$1.2M	Hold	263,529	–	–	0.09%	96
2020 Q4	$1.51M	Hold	263,529	–	–	0.1%	94
2020 Q3	$1.91M	Hold	263,529	–	–	0.17%	78
2020 Q2	$920K	Sell	263,529 -368,858	-58%	-$1.06M	0.09%	91
2020 Q1	$936K	Sell	632,387 -135,755	-18%	-$228K	0.09%	87
2019 Q4	$1.51M	Hold	768,142	–	–	0.13%	82
2019 Q3	$3.93M	Sell	768,142 -65,954	-8%	-$399K	0.44%	32
2019 Q2	$5.93M	Buy	834,096 +42,000	+5%	+$476K	0.39%	41
2019 Q1	$10.5M	Hold	792,096	–	–	0.67%	22
2018 Q4	$6.2M	Buy	792,096 +328,289	+71%	+$3.12M	0.37%	36
2018 Q3	$5.15M	Buy	+463,807	New	+$5.76M	0.25%	48

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fosun International's CBAY Position: Q1 2023 in Review

Fosun International sold out of Cymabay Therapeutics (CBAY) in Q1 2023, closing a stake of 78,529 shares — an estimated $492K sold.

Fosun International first reported a position in CBAY in Q3 2018 and held it in 18 quarters. The position peaked at $10.5M in Q1 2019. 139 funds tracked by Wall St. Rank hold CBAY as of Q1 2023.

Fosun International reported no remaining Cymabay Therapeutics position as of Q1 2023 after selling out during the quarter.
Fosun International sold 78,529 Cymabay Therapeutics shares in Q1 2023, an estimated $492K.
Fosun International first reported a position in Cymabay Therapeutics in Q3 2018 and held it in 18 quarters.
Fosun International's Cymabay Therapeutics position peaked at $10.5M in Q1 2019.
139 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2023.

Based on Fosun International's 13F filing for Q1 2023, filed 28 Apr 2023.